Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: COVID-19 NVX-CoV2373 Vaccine (Novavax) TM
Active ingredients: covid-19 (nvx-cov2373) vaccine
What it is used for
NUVAXOVID has provisional approval for the indication:,Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.,The use of this vaccine should be in accordance with official recommendations.,The decision has been made on the basis of short-term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 9 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
a colourless to slightly yellow, clear to mildly opalescent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient covid-19 (nvx-cov2373) vaccine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
COVID-19 vaccine development landscape | NCIRS
COVID-19 vaccine development landscape COVID-19 Aboriginal and Torres Strait Islander immunisation Australian Immunisation Handbook AusVaxSafety Clinical research COSSI COVID-19 NCIRS COVID-19 response COVID-19 vaccine development landscape COVID-19 vaccines: Frequently asked questions COVID-19 and children: Frequently asked questions Serosurveillance for SARS-CoV-2 COVID-19 vaccination program in Australia COVID-19 in educational settings Disease surveillance and epidemiology Education and training New South Wales Immunisation Specialist Service (NSWISS) Paediatric Active Enhanced Disease Surveillance (PAEDS) PHN Immunisation Support program Population health Program evaluation Regional and global collaborations Research to inform policy Sharing Knowledge About Immunisation (SKAI) Serosurveillance Social science in immunisation Vaccine coverage Vaccine safety In response to the COVID-19 pandemic, our policy support team has been closely monitoring publicly available information on COVID-19 vaccine candidates
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
COVID-19 vaccines: Frequently asked questions | NCIRS
COVID-19 vaccines: Frequently asked questions COVID-19 Aboriginal and Torres Strait Islander immunisation Australian Immunisation Handbook AusVaxSafety Big data Clinical research COSSI COVID-19 NCIRS COVID-19 response COVID-19 vaccine development landscape COVID-19 vaccines: Frequently asked questions COVID-19 vaccination program in Australia Disease surveillance and epidemiology Education and training New South Wales Immunisation Specialist Service (NSWISS) Paediatric Active Enhanced Disease Surveillance (PAEDS) PHN Immunisation Support program Program evaluation Regional and global collaborations Research to inform policy Sharing Knowledge About Immunisation (SKAI) Serosurveillance Social science in immunisation Vaccine coverage Vaccine safety We have provided answers to some of the most frequently asked questions about COVID-19 vaccines
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
COVID-19 and children: Frequently asked questions | NCIRS
COVID-19 and children: Frequently asked questions COVID-19 Aboriginal and Torres Strait Islander immunisation Australian Immunisation Handbook AusVaxSafety Clinical research COSSI COVID-19 NCIRS COVID-19 response COVID-19 vaccine development landscape COVID-19 vaccines: Frequently asked questions COVID-19 and children: Frequently asked questions Serosurveillance for SARS-CoV-2 COVID-19 vaccination program in Australia COVID-19 in educational settings Disease surveillance and epidemiology Education and training New South Wales Immunisation Specialist Service (NSWISS) Paediatric Active Enhanced Disease Surveillance (PAEDS) PHN Immunisation Support program Population health Program evaluation Regional and global collaborations Research to inform policy Sharing Knowledge About Immunisation (SKAI) Serosurveillance Social science in immunisation Vaccine coverage Vaccine safety Children aged 5 years and older are recommended to get COVID-19 vaccine
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
Top results
